Gastric intestinal metaplasia: subtypes and natural history

H M T El-Zimaity, J Ramchatesingh, M Ali Saeed, D Y Graham

Abstract
Background—It has been suggested that the subtyping of intestinal metaplasia in the stomach is useful in stratifying patients with regard to risk of developing gastric cancer.
Aim—To determine whether subtyping intestinal metaplasia provided useful information regarding the natural history of intestinal metaplasia.
Methods—The study used large cup gastric biopsy specimens from predetermined locations (gastric mapping). Follow up biopsies were obtained at one, two, and/or nine years. Biopsies with intestinal metaplasia were stained with high iron diamine/Alcian blue (HID/AB) to determine whether they expressed neutral mucins, sialomucins, or sulphomucins.
Results—Seventy nine patients with intestinal metaplasia were studied and characterised with regard to the most advanced subtype of intestinal metaplasia. The most severe type of intestinal metaplasia was type II in 33 patients and type III in 34 patients. Helicobacter pylori was cured in 67 patients. Follow up showed that changes in type of metaplasia (apparent regression or progression) occurred in both directions and were independent of H pylori status. For example, biopsy sites with “loss” of metaplasia at a follow up visit might have it “reappear” at a subsequent visit. During follow up, no patient developed gastric dysplasia or died from gastric cancer.
Conclusion—HID subtyping did not provide useful information to the clinician or the pathologist. The data are consistent with the notion that the pattern, extent, and severity of atrophy with or without intestinal metaplasia is a far more important predictor of increased cancer risk than intestinal metaplasia subtype.

(J Clin Pathol 2001;54:679–683)

Keywords: Helicobacter pylori; intestinal metaplasia; high iron diamine; gastric cancer

Intestinal-type gastric carcinoma is frequently accompanied by widespread intestinal metaplasia. Gastric cancer is believed to arise via a multi-stage process that includes chronic gastritis, gastric atrophy, usually with intestinal metaplasia, and finally dysplasia. It remains unclear whether intestinal metaplasia is a premalignant condition or a marker for increased risk of malignancy. The fact that intestinal metaplasia in the antrum is also found with duodenal ulcer disease, a condition associated with a low risk for the development of gastric cancer, suggests that other conditions or events are important in the pathogenesis of gastric cancer.

The risk of developing gastric adenocarcinoma is highest in those with the most extensive atrophy associated with hypochlorhydria or achlorhydria. It has been suggested that there is a relation between cancer risk and the subtype of intestinal metaplasia, with the incidence of cancer being highest among patients with intestinal metaplasia subtype III. Confirmation of this hypothesis would suggest that typing of intestinal metaplasia could provide a simple approach to identify those at highest risk, and would allow resources to be directed to surveillance of that small group. Our study was designed to ask whether the results regarding the presence and type of intestinal metaplasia are reproducible or consistent on follow up of the same individual and whether type III metaplasia led to a high frequency of dysplasia.

Materials and methods
Patients
Mucosal biopsy specimens were obtained from patients who had previous upper gastrointestinal endoscopy with gastric mapping. Cases included patients with documented intestinal metaplasia who received surveillance endoscopy at six to 12 month intervals for up to nine years, and included patients in whom Helicobacter pylori infection had been treated successfully, in addition to treatment failures. Indications for upper gastrointestinal endoscopy included duodenal ulcer disease, gastric ulcer, non-ulcer dyspepsia, suspected mucosal associated lymphoid tissue lymphoma, volunteers, gastro-oesophageal reflux disease, or a previous diagnosis of intestinal metaplasia.

Biopsy specimens
Each specimen was placed in a separate bottle of formalin and routinely processed. Serial sections were cut at 5 μm and stained with a triple stain, either the Genta stain or El-Zimaity triple stain. Each specimen was reviewed by one pathologist and scored using a visual analogue scale from 0 (absent/normal) to 5 (maximal intensity) for H pylori and intestinal metaplasia.

High iron diamine staining
Biopsies with intestinal metaplasia were stained with high iron diamine/Alcian blue (HID/AB) to identify neutral mucins, sialomucins, and sulphomucins. Briefly, slides were immersed in...
Results

PATIENTS

Seventy nine patients, five women and 74 men (median age, 60; range, 32–80 years) were studied. Sixty seven patients were cured of H pylori infection; 12 remained infected at follow up. Follow ups were available at one year (n = 74), two years (n = 28), and nine years (n = 36). Three to 12 large cup (RADIAL JAW; MicroVasive, Watertown, Massachusetts, USA) gastric biopsy specimens were obtained from predetermined locations (fig 1). The minimal set was three, consisting of two antral (sites A3 and A4) and one corpus biopsy (site B6).

PATIENTS NEGATIVE FOR H PYLORI AT FOLLOW UP

Sixty seven patients had a total of 1970 biopsies examined (average, 72/patient); 556 biopsies had intestinal metaplasia and were evaluated with HID/AB. Scoring was done according to the most advanced type of intestinal metaplasia. At the first visit, subtype II was present in 33 patients and subtype III was present in 34 patients (table 1).

One year follow up

Twenty three of the 33 patients initially classified with type II intestinal metaplasia had intestinal metaplasia type II at follow up; five had apparent regression to no intestinal metaplasia and five had undergone apparent progression to intestinal metaplasia type III.

Only 18 of the 33 patients initially classified as intestinal metaplasia type III had type III intestinal metaplasia at one year; 15 had apparently “regressed”, with eight having no metaplasia and seven having intestinal metaplasia type II.

Two year follow up

Twelve patients initially classified as type II intestinal metaplasia were evaluated two years after treatment. Type II intestinal metaplasia was present in seven; two had “progressed” to type III and three had no metaplasia found.

Thirteen of 34 patients initially classified as type III were evaluated after two years; no metaplasia was found in three and eight had regressed to intestinal metaplasia type II.

Nine year follow up

Five of the 33 patients initially classified as type II intestinal metaplasia died of unrelated diseases. Seven patients were evaluated at the nine year follow up: three had no metaplasia, three had intestinal metaplasia type II, and one had intestinal metaplasia type III.

Six of the 34 patients initially classified as type III intestinal metaplasia died of unrelated illnesses. Nine patients were evaluated and one had no metaplasia, five had intestinal metaplasia type II, and three had intestinal metaplasia type III.

PATIENTS WITH PERSISTENT H PYLORI INFECTION

Twelve patients had persistent H pylori infection. A total of 250 biopsies were examined (average, 21/patient); 56 biopsies had intestinal metaplasia and were evaluated with HID/AB.

Table 1 Intestinal metaplasia subtype follow up in patients cured of Helicobacter pylori infection

<table>
<thead>
<tr>
<th>Subtype at day 1</th>
<th>N</th>
<th>Subtype</th>
<th>1 year (n)</th>
<th>2 years (n)</th>
<th>6–9 years (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>III</td>
<td>34</td>
<td>0</td>
<td>8</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>I or II</td>
<td>7</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>III</td>
<td>18</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No biopsy</td>
<td>1</td>
<td>21</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Died</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
<tr>
<td>II</td>
<td>33</td>
<td>0</td>
<td>5</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>I or II</td>
<td>23</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>III</td>
<td>5</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No biopsy</td>
<td>0</td>
<td>21</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Died</td>
<td>0</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>

Data are analysed by patient.
Table 2  Follow up of intestinal metaplasia subtypes in treatment failures

<table>
<thead>
<tr>
<th>Subtype at day 1</th>
<th>n</th>
<th>Subtype</th>
<th>1 year (n)</th>
<th>2 years (n)</th>
<th>6–9 years (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>III</td>
<td>6</td>
<td>I or II</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>III</td>
<td>4</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No biopsy</td>
<td>0</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Died</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>II</td>
<td>6</td>
<td>I or II</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>III</td>
<td>1</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No biopsy</td>
<td>4</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Died</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Data are analysed by patient.

Table 2 summarises the data. Six patients were initially classified as type III. At one year follow up, four continued to have type III intestinal metaplasia and two regressed to no metaplasia or type II intestinal metaplasia. At nine years, two of the six remaining patients had died of unrelated causes. Two were re-evaluated and one had no metaplasia and one had intestinal metaplasia type II. Six of these patients were initially classified as having intestinal metaplasia type II. Two were evaluated at one year follow up and one had no metaplasia and one had intestinal metaplasia type II. Five patients were evaluated after nine years and two continued to have intestinal metaplasia subtype II, one had apparent progression to type III, and two had no metaplasia.

ANALYSIS BY BIOPSY SITE
At the first visit, 28 of 202 biopsies (14%) were type I, 109 (54%) were type II, and 65 (32%) were type III. Changes in type of metaplasia in both directions were seen independent of the presence of absence of Helicobacter pylori. For example, in 11% of biopsy sites, metaplasia disappeared at one follow up visit but reappeared at a subsequent visit (table 3).

ANALYSIS ACCORDING TO REGION
To obtain a better representation of the distribution of intestinal metaplasia we performed a subgroup analysis restricted to 39 patients with more than five biopsies obtained at multiple visits, including 29 cured of the infection and 10 with persistent infection. The data were analysed according to the two working hypotheses: the presence of intestinal metaplasia in both the antrum and corpus has a worse prognosis than presence in the antrum only, and intestinal metaplasia with a visual analogue scale score of 5 is worse than that with a visual analogue scale of 1.

Table 3  Changes in type of metaplasia in both directions were seen independent of the presence of Helicobacter pylori or cure of the infection

<table>
<thead>
<tr>
<th>Patient</th>
<th>Visit</th>
<th>A1</th>
<th>A2</th>
<th>A3</th>
<th>A4</th>
<th>A5</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Day 0</td>
<td>III</td>
<td>0</td>
<td>I</td>
<td>II</td>
<td>II</td>
</tr>
<tr>
<td></td>
<td>1 month</td>
<td>0</td>
<td>II</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>6 months</td>
<td>0</td>
<td>II</td>
<td>0</td>
<td>0</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>1 year</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>B</td>
<td>Day 0</td>
<td>III</td>
<td>II</td>
<td>III</td>
<td>II</td>
<td>I</td>
</tr>
<tr>
<td></td>
<td>2 months</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>I</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>8 months</td>
<td>III</td>
<td>I</td>
<td>III</td>
<td>II</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td>1 year</td>
<td>III</td>
<td>III</td>
<td>II</td>
<td>III</td>
<td>II</td>
</tr>
</tbody>
</table>

A1–5 correspond to biopsy sites in the antrum.
Numbers given in columns are the type of metaplasia identified at that visit.
ND, not determined.

Patients cured of H pylori infection
After H pylori eradication, intestinal metaplasia status regressed in 18 patients, eight of whom initially had incomplete intestinal metaplasia type III. Apparent regression occurred irrespective of initial intestinal metaplasia subtype. Two patients had the same score before and after treatment with a 65 month follow up (intestinal metaplasia score was 4 and 5).

Patients with persistent H pylori infection
At presentation, all 10 patients had intestinal metaplasia in both the antrum and corpus and eight had intestinal metaplasia in both regions at subsequent visits. The two patients who did not appear to have intestinal metaplasia in subsequent visits had initial scores for intestinal metaplasia of 1.

Comparison of patients with intestinal metaplasia in both the antrum and corpus showed that the intestinal metaplasia status was unchanged in eight of 10 patients with persistent H pylori compared with 11 of 29 in whom the infection was cured (p = 0.03). When the comparison was done based on initial intestinal metaplasia score, no significant difference was observed between groups. For example, 13 patients who were subsequently cured of the infection had an initial intestinal metaplasia score ≥ 3. On follow up, four showed apparent regression, eight showed no change, and one showed apparent progression. By comparison, in the untreated group, five had an initial intestinal metaplasia score ≥ 3. No changes were seen in any of the patients (p = 0.27).

Discussion
The association between gastric intestinal metaplasia and adenocarcinoma of the stomach is well known. Because the development of gastric carcinoma is slow and unpredictable, investigators have searched for premalignant markers of increased risk for gastric cancer. Intestinal metaplasia subtyped as III is often considered an ominous precursor lesion for the intestinal form of gastric cancer. Biopsy of the same areas of the stomach during follow up for up to nine years showed that neither the presence nor type of intestinal metaplasia was consistent, and that the type of metaplasia appeared to change in both directions. Areas of intestinal metaplasia (or a certain subtype) are generally small (fig 2), so that sampling error is probably responsible for the fact that an approximately equal number of studies have suggested that intestinal metaplasia regresses or does not regress after H pylori eradication. Sampling bias cannot be completely overcome by using targeted biopsies and jumbo forceps. Moreover, H pylori eradication did not decrease the likelihood of finding intestinal metaplasia in subsequent biopsies when comparisons were made between patients with the same initial score for intestinal metaplasia. Recent studies have shown that mucin protein expression is similar in types II and III intestinal metaplasia, so that examining the patterns of mucin protein expression cannot be used as a surrogate for the identification of type III intestinal metaplasia, and challenging the
hypothesis that type II intestinal metaplasia consistently evolves into type III. 36 Our study hypothesizes that type II intestinal metaplasia may evolve into type III among type II intestinal metaplasia; certain subtypes are small and could easily go unsampled at initial procedures.

Figure 2 In general, areas of intestinal metaplasia or a lesion is unknown. In our series, 18% of patients initially classified as intestinal metaplasia type III are closely followed up. The incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut 1991;32:110–13.


7th European Forum on Quality Improvement in Health Care
21–23 March 2002
Edinburgh, Scotland

We are delighted to announce this forthcoming conference in Edinburgh. Authors are invited to submit papers (call for papers closes on Friday 5 October 2001) and delegate enquiries are welcome.

The themes of the Forum are:
- Leadership, culture change, and change management
- Achieving radical improvement by redesigning care
- Health policy for lasting improvement in health care systems
- Patient safety
- Measurement for improvement, learning, and accountability
- Partnership with patients
- Professional quality: the foundation for improvement
- Continuous improvement in education and training
- People and improvement.

Presented to you by the BMJ Publishing Group (London, UK) and Institute for Healthcare Improvement (Boston, USA). For more information contact: quality@bma.org.uk or look at the website www.quality.bmjgroup.com. Tel: +44 (0)20 7383 6409; fax: +44 (0)20 7373 6869.